التفاصيل البيبلوغرافية
| العنوان: |
Repurposed Effect of 177 Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma. |
| المؤلفون: |
Elajami, Mohamad K., Burton, Lorena P., Bahmad, Hisham F., Chaaya, Gerard, Schwartz, Michael |
| المصدر: |
Current Oncology; Oct2022, Vol. 29 Issue 10, p7552-7557, 6p, 1 Color Photograph |
| مصطلحات موضوعية: |
MANTLE cell lymphoma, CARCINOID, CARCINOGENESIS, SOMATOSTATIN, LUNG tumors |
| مستخلص: |
Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium 177Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium 177Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium 177Lu-DOTATATE. After treatment, there was an overall improvement of the patient's MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that 177Lu-DOTATATE might have a role and can be repurposed for treating MCL. [ABSTRACT FROM AUTHOR] |
|
Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder